Osteoarthritis year in review 2021: epidemiology & therapy

QUICKE, J.G., CONAGHAN, P.G., CORP, N. and PEAT, George (2022). Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis and Cartilage, 30 (2), 196-206.

Peat-OsteoarthritisYearReview(VoR).pdf - Published Version
Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
Peat-OsteoarthritisYearReview(Supp).pdf - Supplemental Material
Creative Commons Attribution Non-commercial No Derivatives.

Download (98kB) | Preview
Official URL: https://www.sciencedirect.com/science/article/pii/...
Open Access URL: https://www.sciencedirect.com/science/article/pii/... (Published version)
Link to published version:: https://doi.org/10.1016/j.joca.2021.10.003


This “Year in review” presents a selection of research themes and individual studies from the clinical osteoarthritis (OA) field (epidemiology and therapy) and includes noteworthy descriptive, analytical-observational, and intervention studies. The electronic database search for the review was conducted in Medline, Embase and medRxiv (15th April 2020 to 1st April 2021). Following study screening, the following OA-related themes emerged: COVID-19; disease burden; occupational risk; prediction models; cartilage loss and pain; stem cell treatments; novel pharmacotherapy trials; therapy for less well researched OA phenotypes; benefits and challenges of Individual Participant Data (IPD) meta-analyses; patient choice-balancing benefits and harms; OA and comorbidity; and inequalities in OA. Headline study findings included: a longitudinal cohort study demonstrating no evidence for a harmful effect of non-steroidal anti-inflammatory drugs (NSAIDs) in terms of COVID-19 related deaths; a Global Burden of Disease study reporting a 102% increase in crude incidence rate of OA in 2017 compared to 1990; a longitudinal study reporting cartilage thickness loss was associated with only a very small degree of worsening in pain over 2 years; an exploratory analysis of a non-OA randomised controlled trial (RCT) finding reduced risk of total joint replacement with an Interleukin -1β inhibitor (canakinumab); a significant relationship between cumulative disadvantage and clinical outcomes of pain and depression mediated by perceived discrimination in a secondary analysis from a RCT; worsening socioeconomic circumstances were associated with future arthritis diagnosis in an innovative natural experiment (with implications for unique research possibilities arising from the COVID-19 pandemic context).

Item Type: Article
Uncontrolled Keywords: COVID-19; Clinical; Epidemiology; Osteoarthritis; Review; Treatment; Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Comorbidity; Disease Management; Global Health; Humans; Incidence; Osteoarthritis; Humans; Osteoarthritis; Anti-Inflammatory Agents, Non-Steroidal; Incidence; Comorbidity; Disease Management; Global Health; COVID-19; Arthritis & Rheumatology; 0903 Biomedical Engineering; 1103 Clinical Sciences; 1106 Human Movement and Sports Sciences
Identification Number: https://doi.org/10.1016/j.joca.2021.10.003
Page Range: 196-206
SWORD Depositor: Symplectic Elements
Depositing User: Symplectic Elements
Date Deposited: 29 Jul 2022 13:48
Last Modified: 02 May 2024 08:01
URI: https://shura.shu.ac.uk/id/eprint/30526

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics